Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Period	PE Ratio
2016-12-31	N/A
2017-12-31	52.95
2018-12-31	92.86
2019-12-31	73.61
2020-12-31	65.61
2021-12-31	62.23
2022-12-31	63.54
2023-12-31	59.18
2024-12-31	44.71
2025-12-31	63.54

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CORT	$60.36	+0.23%	0.68M
3
4
5

Corcept Therapeutics Incorporated (CORT) PE Ratio

PE Ratio Data

Get Corcept Therapeutics Incorporated Data in Excel

More CORT Financial Data